In this episode, I sat down with Professor Jodhbir S Mehta to talk about something we don’t discuss enough in medicine: the economy behind innovation. We went beyond “new tech is cool” and focused on the real bottleneck—implementation. It’s not that the public won’t accept new technology; it’s that moving research into the public domain is blocked by stakeholders, funding limits, and policy decisions. Governments have a fixed “pot of money,” and every new program has to prove value: how many patients can we treat, and how do we keep the population healthy over time—especially as aging drives more chronic disease. Professor Mehta shared a really practical way to make innovation more adoptable: speak the language of policymakers. He gave the example of lamellar corneal surgery versus full-thickness penetrating keratoplasty—if you monetize outcomes (fewer regrafts, longer graft survival, less medication) and run cost analyses over 5–10 years, the case becomes compelling for health systems. We also linked this to AI screening in diabetic retinopathy: if AI can screen more people and reduce morbidity, you can compare costs against staffing 25 graders in a reading room. My biggest takeaway is simple: to make medicine accessible, we need outcomes data for clinicians—and economic data for decision-makers. And honestly, we also need to “make medicine sexy” by communicating innovation clearly through media and social platforms so the public stays excited and engaged.